Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
A new final rule from the FDA clarifies for manufacturers when the agency will regulate tobacco products as drugs or devices.
The rule, released by the Food and Drug Administration Jan. 6, describes the circumstances in which a product made or derived from tobacco that is intended for human consumption will be subject to regulation as a drug, device or a combination drug/device product under the Federal Food, Drug, and Cosmetic Act (the FD&C Act).
The FDA said the final rule (RIN:0910-AH19) will help companies that intend to market tobacco products, and investigators planning to study tobacco products for medical uses, to determine the requirements that apply to their proposed studies. The agency also said the rule will help consumers distinguish between tobacco products that are intended for medical use from products marketed for other uses.
As part of the rule, the agency said unless there are “extraordinary circumstances,” it doesn’t consider a company “as intending an unapproved new use for an approved or cleared medical product based solely on that firm’s knowledge that such product was being prescribed or used by doctors for such use.”
This clarifies that manufacturers aren’t promoting off-label uses of their products if they just know how doctors are using their products, Bradley Merrill Thompson, a Washington-based attorney with Epstein Becker & Green PC, told Bloomberg BNA in a Jan. 6 e-mail. While doctors can prescribe medical products for unapproved uses, manufacturers are prohibited from promoting such uses.
The rule’s statement on off-label promotion is a “big clarification,” he said. Thompson counsels medical device, drug, and combination product companies on a wide range of FDA regulatory and clinical trial issues.
Jim Stansel, general counsel for the Pharmaceutical Research and Manufacturers of America (PhRMA), told Bloomberg BNA in an e-mail PhRMA is disappointed the rule “disregards the rulings of multiple courts protecting the right of free speech.”
The rule will be published Jan. 9 in the Federal Register is effective Feb. 8.
“For years we struggled to understand intended use, and the potential impact of mere knowledge of an off-label use. And indeed, those concerns grew out of the tobacco litigation many years ago where that theory was advanced,” Thompson said. “So it’s only fitting that in the tobacco realm FDA is now putting to rest that concern.”
Thompson said “this is a matter of fundamental fairness, because off-label promotion is potentially a criminal violation. And it always seemed to me to be a stretch to argue that someone could be effectively off-label promoting if they did absolutely nothing to promote the off-label use, but merely knew that’s how other people were using their product. So this is an extremely healthy revision.”
“The FDA acknowledges that doctors are allowed to prescribe pharmaceutical products for uses not included in the drug label the agency approved. In fact, these unapproved uses are often the accepted treatment for particular illnesses, including many forms of cancer,” PhRMA's Stansel said. “But the FDA’s rule could lead to restrictions on the dissemination of truthful and non-misleading information that would otherwise be used to help physicians and payers in their decision-making.”
Stansel said “this is bad medicine for patients and is inconsistent with decisions of the Supreme Court and lower courts granting first amendment protections to truthful and nonmisleading communications of clinical information.”
A spokesman for the Advanced Medical Technology Association (AdvaMed), a device makers' group, told Bloomberg BNA the group has “no comment” on the final rule.
The Family Smoking Prevention and Tobacco Control Act, a 2009 law, amended the FD&C Act to provide the FDA with the authority to regulate tobacco products, the FDA said. Excluded from the definition of a tobacco product is any article that is a drug, device or combination product.
Under the final rule, a tobacco product intended for human consumption is regulated as a drug, device or combination product if:
The rule also clarifies the remaining circumstances where a product is subject to regulation as a tobacco product, the FDA said.
To contact the reporter on this story: Bronwyn Mixter in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Brian Broderick at email@example.com
The rule is at http://src.bna.com/lcM.
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)